My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Novo Nordisk A/S Common Stock (NY:NVO)

48.10 UNCHANGED

Streaming Delayed Price Updated: 7:00 PM EST, Dec 22, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

99 100 Next >

Novo Nordisk A/S (NVO) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

June 25, 2025

From Law Offices of Howard G. Smith

Via Business Wire

Abbott, Dexcom Draw Retail Buzz As RFK Jr. Urges Americans To Embrace Health Wearables ↗

June 25, 2025

Retail sentiment surged on Stocktwits, with message volume jumping 1,600% for Abbott and 750% for Dexcom.

Via Stocktwits

Hims & Hers CEO Says 'No Way In Hell We're Gonna Cave On' Selling Compounded Obesity Drugs After Novo Nordisk Breakup ↗

June 24, 2025

Truist warned that Hims faces renewed litigation risk after Novo's exit, which could create a prolonged legal overhang on the stock.

Via Stocktwits

Topics Law Enforcement Lawsuit

Securities Fraud Investigation Into Novo Nordisk A/S (NVO) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

June 24, 2025

From The Law Offices of Frank R. Cruz

Via Business Wire

HIMS Crashes On Novo GLP-1 Fallout: Buy The Dip Or Bail? ↗

June 24, 2025

Telehealth company Hims & Hers (HIMS) saw a 34% stock drop after Novo Nordisk (NVO) ended their relationship. Investors must decide if it's a buying opportunity or a warning sign for the industry.

Via Benzinga

Novo's India Move Could Reshape The Weight-Loss Drug War With Eli Lilly ↗

June 24, 2025

Novo Nordisk launches Wegovy in India, pricing it close to Eli Lilly's Mounjaro, while advancing global regulatory efforts for its GLP-1 portfolio.

Via Benzinga

Why Did Hims and Hers Stock Crash on Monday? ↗

June 24, 2025

Via The Motley Fool

Novo Nordisk Has Ended Its Wegovy Deal With Hims & Hers: Here's What Investors Need to Know ↗

June 24, 2025

Via The Motley Fool

Hims & Hers Stock Rebounds After-Hours After Novo Nordisk Split Triggers Record Plunge — Retail Traders Stay Loyal ↗

June 23, 2025

On Stocktwits, 24-hour message volume around HIMS soared 6,717% — the fifth highest among healthcare stocks. It was the top trending ticker on the platform late Monday.

Via Stocktwits

Hims & Hers CEO Hits Back At Novo Nordisk After Abrupt End Of Collaboration, Alleges Wegovy-Maker Is ‘Misleading The Public’ ↗

June 23, 2025

HIMS CEO said that the pharma company’s commercial team has been increasingly pressuring the company to control clinical standards and steer patients to Wegovy regardless of whether it is clinically...

Via Stocktwits

Why Novo Nordisk Stock Is Sinking Today ↗

June 23, 2025

Via The Motley Fool

Topics Stocks Supply Chain

Stocks Rise, Oil Tumbles Despite Iran's Strikes On US Bases: What's Driving Markets Monday? ↗

June 23, 2025

Wall Street resilient as Iran fires missiles at U.S. bases in Qatar and Iraq, defying expectations in energy market. U.S. equities and gold up, bonds down.

Via Benzinga

Topics Bonds

Hims & Hers Stock Plunges As Novo Nordisk Ends Partnership Over Allegations Of Selling Knockoff Versions Of Wegovy ↗

June 23, 2025

Novo said that Hims & Hers failed to adhere to the law, which prohibits mass sales of compounded drugs. It alleged that the telehealth operator is promoting and selling illegitimate, knockoff versions...

Via Stocktwits

Topics Law Enforcement

Hims & Hers Health Stock Is Tumbling Monday: What's Happening? ↗

June 23, 2025

Hims & Hers Health Inc (NYSE:HIMS) shares are trading lower Monday after Novo Nordisk A/S (NYSE:NVO) terminated its collaboration with the company.

Via Benzinga

Novo Nordisk's Weight Loss Injection CagriSema Data Sparks Investor Concern ↗

June 23, 2025

Novo Nordisk's CagriSema achieved significant weight loss in phase 3 trials, though safety concerns may limit its edge over existing and pipeline rivals.

Via Benzinga

IBD 50's Hims Plummets After Novo Yanks Deal Over 'Deceptive' And 'Illegitimate' Wegovy Knockoffs ↗

June 23, 2025

Hims stock plummeted Monday after Novo Nordisk ended their collaboration over concerns about Hims' compounded semaglutide.

Via Investor's Business Daily

Dow Futures Edge Lower As Iran Moves To Block Strait Of Hormuz: Exxon, Chevron, Occidental, Tesla Among Stocks In Focus ↗

June 23, 2025

Via Stocktwits

Topics Stocks

NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) – A Strong Growth Stock with Reasonable Valuation ↗

June 23, 2025

NOVO-NORDISK (NYSE:NVO) offers strong growth, high profitability, and reasonable valuation, making it an attractive candidate for investors seeking affordable growth stocks.

Via Chartmill

Watch Out, Novo Nordisk & Eli Lilly: Chinese Biotech Steps Into the Ring To Take On Global Weight-Loss Leaders ↗

June 23, 2025

Sciwind Biosciences is expanding its global footprint with licensing deals and early talks for overseas development, as it eyes a double-digit market share in China's fast-growing obesity drug sector.

Via Stocktwits

Novo Nordisk Gains Ground In Obesity Race As Amycretin, Wegovy Show Significant Weight Loss ↗

June 22, 2025

The company is advancing amycretin to Phase 3 and pursuing regulatory approval for a higher Wegovy dose.

Via Stocktwits

5 Health Care Stocks With Whale Alerts In Today's Session ↗

June 20, 2025

Via Benzinga

McDonald’s Is Down, But Long-Term Investors Can Still Take a Bite

June 20, 2025

Analysts are downgrading McDonald's and the stock may have further to fall, but as a long-term opportunity, it may be getting to a point of offering real value

Via MarketBeat

How Do Investors Really Feel About Novo Nordisk? ↗

June 19, 2025

Via Benzinga

How IBD 50's Hims & Hers Is Shaking Up The Weight-Loss Brawl ↗

June 19, 2025

This dark horse candidate has emerged to take significant share in the weight-loss drugs space.

Via Investor's Business Daily

NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) - A Strong Candidate for Value Investors ↗

June 19, 2025

NOVO-NORDISK A/S (NYSE:NVO) is a strong value stock with high profitability, solid growth, and an attractive valuation, making it a candidate for long-term investors.

Via Chartmill

Why Scholar Rock Shares Are Soaring Today ↗

June 18, 2025

Via The Motley Fool

Topics Stocks

US Judge Upholds FDA Decision To Remove Wegovy, Ozempic From Shortage List In Move Against Compounding Pharmacies ↗

June 18, 2025

The judge said that the FDA had appropriately weighed supply and demand data for the drugs and properly removed them from the shortage list, Reuters reported.

Via Stocktwits

Topics Lawsuit

Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study ↗

June 18, 2025

Scholar Rock's apitegromab helped preserve muscle mass during tirzepatide-induced weight loss, improving overall body composition in Phase 2 trial.

Via Benzinga

Novo Nordisk Just Improved Its Weight-Management Pipeline: Is the Stock a Buy? ↗

June 18, 2025

Via The Motley Fool

Topics Artificial Intelligence

Novel Diagnostic Technology Disrupting Diabetic Retinopathy Market Generating Billions in Revenue Opportunities

June 17, 2025

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TNDM),(NYSE:NVO),(NASDAQ:PODD),(NYSE:MDT) EQNX::TICKER_END

Via FinancialNewsMedia

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.